Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Jiao, Yisheng ^a   Ou, Wenbin ^b   Meng, Fanguo ^b   Zhou, Haimeng ^b   Wang, Aiyuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

Coactivation; Hsp90; Ovarian cancer; Tyrosine kinases

Indexed keywords

AUY 922; BETA ACTIN; CASPASE 8; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN AXL; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; RAF PROTEIN; SCATTER FACTOR RECEPTOR; TANESPIMYCIN; UNCLASSIFIED DRUG; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; AXL RECEPTOR TYROSINE KINASE; BENZOQUINONE DERIVATIVE; ERBB2 PROTEIN, HUMAN; MACROCYCLIC LACTAM; MET PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; RECEPTOR TYROSINE PROTEIN KINASE ERBB 4; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INACTIVATION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOLECULARLY TARGETED THERAPY; OVARY TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 80053364033     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-125     Document Type: Article

References (54)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J Clin 2003, 53:5-26. 10.3322/canjclin.53.1.5, 12568441.
2. Campos SM, Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol 2010, 2010:149362. 2804109, 20069122.
3. Siwak DR, Carey M, Hennessy BT, Nguyen CT, Gahren Murray MJ, Nolden L, Mills GB. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010, 2010:568938. 2796463, 20037743.
4. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001, 38:87-95. 10.1046/j.1365-2559.2001.01042.x, 11207821.
5. Baek SJ, Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol 2008, 19:223-228. 10.3802/jgo.2008.19.4.223, 2676474, 19471577.
6. Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, Butzow R. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 2006, 84:671-681. 10.1007/s00109-006-0054-4, 16607561.
7. Stadlmann S, Gueth U, Reiser U, Diener PA, Zeimet AG, Wight E, Mirlacher M, Sauter G, Mihatsch MJ, Singer G. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 2006, 19:607-610. 10.1038/modpathol.3800575, 16554736.
8. Vermeij J, Teugels E, Bourgain C, Xiangming J, in 't Veld P, Ghislain V, Neyns B, Greve JD. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 2008, 8:3. 10.1186/1471-2407-8-3, 2266762, 18182111.
9. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009, 9:433. 10.1186/1471-2407-9-433, 2803495, 20003286.
10. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004, 22:3126-3132. 10.1200/JCO.2004.11.154, 15284264.
11. Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010, 116:15-20. 10.1016/j.ygyno.2009.09.025, 2804260, 19840887.
12. Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, Zaghlul S, Batt D, Ettenberg S, Meyerson M, Schoeberl B, Kung AL, Hahn WC, Drapkin R, Livingston DM, Liu JF. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010, 17:298-310. 10.1016/j.ccr.2009.12.047, 2897158, 20227043.
13. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007, 67:1670-1679. 10.1158/0008-5472.CAN-06-1147, 17308108.
14. Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia 2010, 12:1-10. 2805878, 20072648.
15. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim H, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2009, 101:1193-1205. 10.1093/jnci/djp231, 2736292, 19641174.
16. Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer 2009, 101:1699-1708. 10.1038/sj.bjc.6605381, 2778533, 19861960.
17. Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler IJ. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol 2004, 93:78-86. 10.1016/j.ygyno.2003.12.041, 15047217.
18. Lassus H, Sihto H, Leminen A, Nordling S, Joensuu H, Nupponen NN, Butzow R. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer 2004, 91:2048-2055. 10.1038/sj.bjc.6602252, 2409787, 15583695.
19. Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C, Donner DD. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 2006, 25:2060-2069. 10.1038/sj.onc.1209232, 16331269.
20. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 1999, 5:587-591.
21. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, Sugisaki Y. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000, 83:196-203. 2363477, 10901370.
22. Sun W, Fujimoto J, Tamaya T. Coexpression of Gas6/Axl in human ovarian cancers. Oncology 2004, 66:450-457. 10.1159/000079499, 15452374.
23. Vang R, Shih I, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009, 16:267-82. Review, 10.1097/PAP.0b013e3181b4fffa, 2745605, 19700937.
24. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010, 221:49-56. 10.1002/path.2696, 20229506.
25. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998, 16:2659-2671.
26. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480. 10.1056/NEJMoa020461, 12181401.
27. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037. 10.1056/NEJM200104053441401, 11287972.
28. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
29. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA. KIT Activation Is a Ubiquitous Feature of Gastrointestinal Stromal Tumor. Cancer Res 2001, 61:8118-8121.
30. Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia 2011, 13:12-22. 3022424, 21245936.
31. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004, 206:149-157. 10.1016/j.canlet.2003.08.032, 15013520.
32. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and matastasis. Cancer Res 2008, 68:2850-2860. 10.1158/0008-5472.CAN-07-5256, 18413753.
33. Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, Kohn EC. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 2010, 16:664-672. 10.1158/1078-0432.CCR-09-2308, 2943831, 20068097.
34. Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2008, 26:3418-3425. 10.1200/JCO.2007.14.3420, 18612157.
35. Xu AM, Huang PH. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 2010, 70:3857-3860. 10.1158/0008-5472.CAN-10-0163, 2875162, 20406984.
36. Corps AN, Sowter HM, Smith SK. Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met. Int J Cancer 2001, 73:151-155.
37. Wong AS, Pelech SL, Woo MM, Yim G, Rosen B, Ehlen T. Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?. Oncogene 2001, 20:1318-1328. 10.1038/sj.onc.1204253, 11313876.
38. Wong AS, Roskelley CD, Pelech S, Miller D, Leung PC, Auersperg N. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res 2004, 299:248-256. 10.1016/j.yexcr.2004.06.002, 15302591.
39. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, Tengg-Kobligk H, Kiessling F, Eichelsbacher U, Essig M, Read TA, Erber R, Ullrich A. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 2006, 103:5799-5804. 10.1073/pnas.0510923103, 1458653, 16585512.
40. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G, Ullrich A. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008, 68:1905-1915. 10.1158/0008-5472.CAN-07-2661, 18339872.
41. Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005, 11:7023-7032. 10.1158/1078-0432.CCR-05-0518, 16203796.
42. Sain N, Krishnan B, Ormerod MG, De RA, Liu WM, Kaye SB, Workman P, Jackman AL. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 2006, 5:1197-1208. 10.1158/1535-7163.MCT-05-0445, 16731752.
43. Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, Akpan A, Yang A, Zvelebil M, Cramer R, Stimson L, Aherne W, Banerji U, Judson I, Sharp S, Powers M, deBilly E, Salmons J, Walton M, Burlingame A, Waterfield M, Workman P. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2007, 67:3239-3253. 10.1158/0008-5472.CAN-06-2968, 17409432.
44. Lu Z, Hunter T. Degradation of activated protein kinases by ubiquitination. Annu Rev Biochem 2009, 78:435-475. 10.1146/annurev.biochem.013008.092711, 2776765, 19489726.
45. Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, Yarden Y. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep 2004, 5:1165-1170. 10.1038/sj.embor.7400300, 1299195, 15568014.
46. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006, 66:9153-9161. 10.1158/0008-5472.CAN-06-0165, 16982758.
47. Moser C, Lang SA, Stoeltzing O. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Anticancer Res 2009, 29:2031-2042.
48. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010, 10:537-549. 10.1038/nrc2887, 20651736.
49. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L, Trepel JB. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009, 9:1479-1492. 10.2174/156802609789895728, 19860730.
50. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M, Sobue G. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005, 11:1088-1095. 10.1038/nm1298, 16155577.
51. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998, 79:129-168. 10.1016/S0163-7258(98)00013-8, 9749880.
52. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005, 16:797-803. 10.1097/01.cad.0000173476.67239.3b, 16096426.
53. Breitkreutz A, Tyers M. Cell signaling. A sophisticated scaffold wields a new trick. Science 2006, 311:789-790. 10.1126/science.1124620, 16469909.
54. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005, 17:596-603. 10.1016/j.ceb.2005.09.009, 16226444.